Business
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. Business Highlights Surrozen has pivoted its focus to its ophthalmology pipeline, leveraging it
About this update from Surrozen, Inc.
[{"type":"image","alt":"Surrozen, Inc.","displaySize":"","headline":null,"caption":"Surrozen, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://ml.globenewswire.com/Resource/Download/1402e192-4e1a-498f-b1b0-f8858e4d4858?size=2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/x6DV722PrEWTqtVALzIaoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://ml.globenewswire.com/Resource/Download/1402e192-4e1a-498f-b1b0-f8858e4d4858?size=2","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_Nw2ZiUnSxKs.uMojTysxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://ml.globenewswire.com/Resource/Download/1402e192-4e1a-498f-b1b0-f8858e4d4858?size=2","width":1200,"height":675}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.","length":404,"tagName":"p"},{"type":"text","content":"Business Highlights","length":19,"tagName":"p"},{"type":"text","content":"Surrozen has pivoted its focus to its ophthalmology pipeline, leveraging its Wnt biology expertise and antibody technologies to develop novel treatments for severe eye diseases, including age-related macular degeneration (AMD) and diabetic retinopathy. The Company discontinued development of SZN-043 for the treatment of severe alcohol-associated hepatitis in the first quarter of 2025 due to insufficient clinical benefit in the Phase 1b trial.","length":446,"tagName":"p"},{"type":"text","content":"The Company has redirected resources to advance its lead ophthalmology candidates SZN-8141 and SZN-8143 toward clinical studies. SZN-8141 combines Frizzled 4 (Fzd4) agonism with VEGF antagonism, while SZN-8143 adds IL-6 antagonism, offering potential differentiation from existing therapies. Surrozen expects to file an Investigational New Drug (IND) application and commence clinical studies for SZN-8141 in 2026. The Food and Drug Administration clearance of this IND application would trigger funding of the $98.6 million private plac...